Compare Ascendis Pharma A/S (ASND) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Schwab US Dividend Equity ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Schwab US Dividend Equity ETF trades at $32.49. Which is the better fit depends on your goals.
| ASND | SCHD | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $32.83 |
52-Week Low | $163.32 | $26.38 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SCHD trades at $32.40, up 0.43% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on U.S. dividend equities, offering a yield around 3.2%, and has shown strong performance in 2026, outpacing the S&P 500. Recent news highlights its appeal for long-term income investors, though some analysts note underperformance concerns versus broader indices.
Outlook remains positive for dividend-focused portfolios, supported by quality stock selection and low fees. Key risks include interest rate sensitivity and market rotation away from value stocks. Institutional sentiment is mixed, with bullish technicals contrasting with fundamental debates on total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
